Serum aspirin esterase is strongly associated with glucose and lipids in healthy subjects: different association patterns in subjects with type 2 diabetes mellitus

Table 1 Clinical characteristics of type 2 diabetic subjects and control subjects

Variables	Controls (N = 20)	Type 2 Diabetics (N = 27)	p value
Age, years	60.1 ± 14.3	55.9 ± 10.0	0.24
Men/women, n	8/12	18/9	0.07
Body mass index, kg/m²	22.1 ± 3.7	22.8 ± 2.6	0.46
Fasting glucose, mmol/L	5.41 ± 0.79	9.13 ± 3.66	< 0.0001**
HbA1c, %	5.0 ± 0.4	7.6 ± 1.3	< 0.0001**
Total cholesterol, mmol/L	5.54 ± 1.10	5.28 ± 0.96	0.48
Triglyceride, mmol/L	1.04 (0.84-1.45)	2.11 (1.93-2.34)	0.13
HDL cholesterol, mmol/L	1.76 ± 0.41	1.40 ± 0.38	0.006**
Albumin, μmol/L	629 ± 27	605 ± 44	0.07
ChE, U/L	319 ± 73	360 ± 74	0.07
Aspirin esterase (nmol/mL/min)	39.2 (32.5-48.7)	41.6 (37.1-46.5)	0.66

HbA1c: hemoglobin A1c, HDL: high-density lipoprotein, ChE: cholinesterase. Data are presented as mean ± standard deviation, median (interquartile range) or number. Triglyceride and aspirin esterase were log-transformed because of their skewed distribution in the statistical analyses. Significance level (t-test or χ²-test between the group with controls and type 2 diabetes): ** p < 0.01.

ISSN: 1758-5996